In a large meta-analysis, Vuong HG et al. demonstrated that PTCs with co-existing BRAFV600E and TERT promoter mutations were associated with a significant increased risk for tumor aggressiveness and recurrence compared to PTCs with BRAF or TERT promoter mutations alone [36]. This evidence concerns the gene BRAF and neoplasm.